Literature DB >> 23992409

Synthetic retinoid Am80 up-regulates apelin expression by promoting interaction of RARα with KLF5 and Sp1 in vascular smooth muscle cells.

Xin-Rui Lv1, Bin Zheng, Shu-Ya Li, Ai-Li Han, Chang Wang, Jian-Hong Shi, Xin-Hua Zhang, Yan Liu, Yong-Hui Li, Jin-Kun Wen.   

Abstract

Previous studies have demonstrated that both retinoids and apelin possess potent cardiovascular properties and that retinoids can mediate the expression of many genes in the cardiovascular system. However, it is not clear whether and how retinoids regulate apelin expression in rat VSMCs (vascular smooth muscle cells). In the present study, we investigated the molecular mechanism of apelin expression regulation by the synthetic retinoid Am80 in VSMCs. The results showed that Am80 markedly up-regulated apelin mRNA and protein levels in VSMCs. Furthermore, KLF5 (Krüppel-like factor 5) and Sp1 (stimulating protein-1) co-operatively mediated Am80-induced apelin expression through their direct binding to the TCE (transforming growth factor-β control element) on the apelin promoter. Interestingly, upon Am80 stimulation, the RARα (retinoic acid receptor α) was recruited to the apelin promoter by interacting with KLF5 and Sp1 prebound to the TCE site of the apelin promoter to form a transcriptional activation complex, subsequently leading to the up-regulation of apelin expression in VSMCs. An in vivo study indicated that Am80 increased apelin expression in balloon-injured arteries of rats, consistent with the results from the cultured VSMCs. Thus the results of the present study describe a novel mechanism of apelin regulation by Am80 and further expand the network of RARα in the retinoid pathway.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23992409     DOI: 10.1042/BJ20130418

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  11 in total

Review 1.  Endoplasmic reticulum stress: a novel mechanism and therapeutic target for cardiovascular diseases.

Authors:  Mei-qing Liu; Zhe Chen; Lin-xi Chen
Journal:  Acta Pharmacol Sin       Date:  2016-02-01       Impact factor: 6.150

2.  Identification of a KLF5-dependent program and drug development for skeletal muscle atrophy.

Authors:  Lin Liu; Hiroyuki Koike; Takehito Ono; Shinichiro Hayashi; Fujimi Kudo; Atsushi Kaneda; Hiroyuki Kagechika; Ichiro Manabe; Tomoki Nakashima; Yumiko Oishi
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-31       Impact factor: 11.205

Review 3.  Temporal Expression of Apelin/Apelin Receptor in Ischemic Stroke and its Therapeutic Potential.

Authors:  Yili Wu; Xin Wang; Xuan Zhou; Baohua Cheng; Gongying Li; Bo Bai
Journal:  Front Mol Neurosci       Date:  2017-01-23       Impact factor: 5.639

Review 4.  The Role of the Apelin/APJ System in the Regulation of Liver Disease.

Authors:  Xinrui Lv; Jing Kong; Wei-Dong Chen; Yan-Dong Wang
Journal:  Front Pharmacol       Date:  2017-04-24       Impact factor: 5.810

5.  Mechanism of KLF4 Protection against Acute Liver Injury via Inhibition of Apelin Signaling.

Authors:  Weitao Ji; Hongyun Shi; Hailin Shen; Jing Kong; Jiayi Song; Hongyan Bian; Xinrui Lv
Journal:  Oxid Med Cell Longev       Date:  2019-10-10       Impact factor: 6.543

6.  Apelin promotes hepatic fibrosis through ERK signaling in LX-2 cells.

Authors:  Ying Wang; Jiayi Song; Hongyan Bian; Jiaqi Bo; Shuangyu Lv; Weitong Pan; Xinrui Lv
Journal:  Mol Cell Biochem       Date:  2019-07-03       Impact factor: 3.396

Review 7.  Apelin/APJ system: A key therapeutic target for liver disease.

Authors:  Shuang-Yu Lv; Binbin Cui; Wei-Dong Chen; Yan-Dong Wang
Journal:  Oncotarget       Date:  2017-12-01

Review 8.  The Protective Effects and Mechanisms of Apelin/APJ System on Ischemic Stroke: A Promising Therapeutic Target.

Authors:  Yanjun Tian; Ruijiao Chen; Yunlu Jiang; Bo Bai; Tongju Yang; Haiqing Liu
Journal:  Front Neurol       Date:  2020-03-03       Impact factor: 4.003

9.  Pioglitazone protects blood vessels through inhibition of the apelin signaling pathway by promoting KLF4 expression in rat models of T2DM.

Authors:  Ying Wang; Ruonan Zhang; Hailin Shen; Jing Kong; Xinrui Lv
Journal:  Biosci Rep       Date:  2019-12-20       Impact factor: 3.840

10.  Reducing FASN expression sensitizes acute myeloid leukemia cells to differentiation therapy.

Authors:  Magali Humbert; Kristina Seiler; Severin Mosimann; Vreni Rentsch; Katyayani Sharma; Amit V Pandey; Sharon L McKenna; Mario P Tschan
Journal:  Cell Death Differ       Date:  2021-03-19       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.